SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome

SciSparc Ltd. (NASDAQ: SPRC ), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration for its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette s yndrome ("TS"). The work towards an IND submission is intended to open a U.S. clinical site that will take part in the phase IIb trial. “We are very excited about expanding our clinical sites to the U.S., especially after positive results obtained in a clinical trial led by professor Bloch M.D., M.S. , an associate professor in the Child Trial Center at Yale University, using our proprietary drug candidate," stated Dr. Adi Zuloff-Shani , SciSparc’ s CTO. "Expanding this trial, is part of our overall efforts to expedite the development of SCI-110 for TS, which is a greatly underserved therapeutic area. We believe our approach has significant advantages over available treatments and ... Full story available on Benzinga.com